Dare I say it, you've chosen a very good entry point.
If Linda is going to impart excellent data on Direct, excellent data on L info arm, and trial partnerships with three different entities, all on Wed 21st at the 5th Annual Cancer Vaccines Conference (proudly sponsored by NWBO!) there will, of course be a market reaction...
For anyone not aware, Roy Baynes, Senior Vice President, Global Development, Merck (pembrolizumab CI) and Daejin Abidoye, Medical Director, Genentech (Roche, Atezolizumab CI) are both in attendance.
And, if she chooses to PR the content in advance, then that might happen towards the end of next week.
If one of the trial combos is, in fact, a strategic partnership with upfront financial inducements coming NWBO's way; well, you've definitely picked the right moment.
Rather a silly phrase 'exclusive updates' on the conference promotional literature. Makes it sound a bit like a tabloid kiss and tell story.
Exclusive to who? Once she gives the updates, it won't be exclusive to anybody. The whole world will know (hopefully!)
Unless it means the updates are going to be exclusively announced at the conference, and not PR'd in advance. Maybe the same morning?
In any event, I'm reasonably confident of a price hike during next week due to the anticipation factor, and no possibility of a toxic, dilutive funding deal.
AI
Market Data 
Markets 
